ACCC COVID-19 Resource Center & Listserv
for Insights on Providing Optimal Patient Care During the Pandemic.
bringing together oncologists and oncology-focused healthcare professionals across the Empire State
Meetings & Education
Financial Advocacy & Patient Assistance
Off-Label Use Literature
Patient Advocacy Organizations
National Professional Organizations
ESHOS Corporate Members
Become a Corporate Member
Industry News Archive
FDA Approves Enhertu for Previously Treated Unresectable or Metastatic HER2+ Breast Cancer
On December 20, 2019, the U.S. Food and Drug Administration (FDA) granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu
, Daiichi Sankyo) for patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting.
Read FDA announcement
Tweets by OSSatACCC